Literature DB >> 25223461

Drug development for hepatocellular carcinoma: knowing the past helps to understand the future.

Stephen L Chan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25223461      PMCID： PMC4221377          DOI： 10.1634/theoncologist.2014-0304

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  20 in total

1.  Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.

Authors:  Bert H O'Neil; Laura W Goff; John Sae Wook Kauh; Jonathan R Strosberg; Tanios S Bekaii-Saab; Ruey-Min Lee; Aslamuzzaman Kazi; Dominic T Moore; Maria Learoyd; Richard M Lush; Said M Sebti; Daniel M Sullivan
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

Review 2.  Targeted therapy of hepatocellular carcinoma: present and future.

Authors:  Stephen L Chan; Winnie Yeo
Journal:  J Gastroenterol Hepatol       Date:  2012-05       Impact factor: 4.029

3.  Management of hepatocellular carcinoma.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2005-11       Impact factor: 17.425

4.  c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.

Authors:  Hanning You; Wei Ding; Hien Dang; Yixing Jiang; C Bart Rountree
Journal:  Hepatology       Date:  2011-07-19       Impact factor: 17.425

5.  Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis.

Authors:  Chien-Hung Chen; Guan-Tarn Huang; Pei-Ming Yang; Pei-Jer Chen; Ming-Yang Lai; Ding-Shinn Chen; Jung-Der Wang; Jin-Chuan Sheu
Journal:  Eur J Cancer       Date:  2006-08-22       Impact factor: 9.162

6.  Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.

Authors:  Ghassan K Abou-Alfa; Philip Johnson; Jennifer J Knox; Marinela Capanu; Irina Davidenko; Juan Lacava; Thomas Leung; Bolorsukh Gansukh; Leonard B Saltz
Journal:  JAMA       Date:  2010-11-17       Impact factor: 56.272

7.  A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

Authors:  Winnie Yeo; Tony S Mok; Benny Zee; Thomas W T Leung; Paul B S Lai; Wan Y Lau; Jane Koh; Frankie K F Mo; Simon C H Yu; Anthony T Chan; Pun Hui; Brigette Ma; Kwok C Lam; Wing M Ho; Herman T Wong; Amanda Tang; Philip J Johnson
Journal:  J Natl Cancer Inst       Date:  2005-10-19       Impact factor: 13.506

8.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy.

Authors:  Stephen L Chan; Frankie K F Mo; Philip J Johnson; Edwin P Hui; Brigette B Y Ma; Wing M Ho; Kwok C Lam; Anthony T C Chan; Tony S K Mok; Winnie Yeo
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544
View more
  5 in total

1.  Systemic chemotherapy with oxaliplatin is a good option for advanced hepatocellular carcinoma.

Authors:  Shukui Qin; Qiong Wu
Journal:  Hepat Oncol       Date:  2015-07-30

Review 2.  Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016.

Authors:  Stephen L Chan; Charing C N Chong; Anthony W H Chan; Darren M C Poon; Kenneth S H Chok
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

3.  β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1.

Authors:  Xiaoqiang Li; Zhenhai Lin; Bo Zhang; Lei Guo; Shuang Liu; Hui Li; Jubo Zhang; Qinghai Ye
Journal:  Sci Rep       Date:  2016-02-12       Impact factor: 4.379

Review 4.  Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment.

Authors:  Zuzana Macek Jilkova; Keerthi Kurma; Thomas Decaens
Journal:  Cancers (Basel)       Date:  2019-10-02       Impact factor: 6.639

Review 5.  Genetically Engineered Mouse Models for Liver Cancer.

Authors:  Kyungjoo Cho; Simon Weonsang Ro; Sang Hyun Seo; Youjin Jeon; Hyuk Moon; Do Young Kim; Seung Up Kim
Journal:  Cancers (Basel)       Date:  2019-12-19       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.